Pharmaceutical medicine

Keyphrases

Publications

volume 38, number 2, 2024

Giulio Napolitano, Canan Has, Anne Schwerk, Jui-Hung Yuan, Carsten Ullrich
Potential of Artificial Intelligence to Accelerate Drug Development for Rare Diseases. Pharmaceutical medicine 38 (2) (2024)
Michael E Kieffer
Why Oncology Global Safety Teams Should Develop the Safety Section of the Study's Target Product Profile (TPP). Pharmaceutical medicine 38 (2) (2024)
Andrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, Dalma Seboek Kinter, Bruno Flamion
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials. Pharmaceutical medicine 38 (2) (2024)
Carolyn Sweeney, Alicia Gilsenan, Brian Calingaert, Carsten Moeller, Gesa Schomakers, Alen Sok, Ruth Holzmann, Federica Pisa
Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures. Pharmaceutical medicine 38 (2) (2024)
Andrea Phillips-Beyer, Ariane K Kawata, Leah Kleinman, Dalma Seboek Kinter, Bruno Flamion
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials. Pharmaceutical medicine 38 (2) (2024)
Thomas Hügle
Advancing Rheumatology Care Through Machine Learning. Pharmaceutical medicine 38 (2) (2024)
Nidhi Mehrotra, Padmavati Manchikanti
Emergency Approval Mechanisms for Human Vaccines in India. Pharmaceutical medicine 38 (2) (2024)
Thomas Hügle
Advancing Rheumatology Care Through Machine Learning. Pharmaceutical medicine 38 (2) (2024)
Carolyn Sweeney, Alicia Gilsenan, Brian Calingaert, Carsten Moeller, Gesa Schomakers, Alen Sok, Ruth Holzmann, Federica Pisa
Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures. Pharmaceutical medicine 38 (2) (2024)
Thomas Hügle
Advancing Rheumatology Care Through Machine Learning. Pharmaceutical medicine 38 (2) (2024)
Shubhadeep D Sinha, Sreenivasa Chary Sriramadasu, Ruby Raphael, Sudeshna Roy
Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges. Pharmaceutical medicine 38 (2) (2024)
Shubhadeep D Sinha, Sreenivasa Chary Sriramadasu, Ruby Raphael, Sudeshna Roy
Decentralisation in Clinical Trials and Patient Centricity: Benefits and Challenges. Pharmaceutical medicine 38 (2) (2024)
Carolyn Sweeney, Alicia Gilsenan, Brian Calingaert, Carsten Moeller, Gesa Schomakers, Alen Sok, Ruth Holzmann, Federica Pisa
Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures. Pharmaceutical medicine 38 (2) (2024)

volume 38, number 3, 2024

Isabel Sanchez-Magro, Susana Gomez-Lus, Javier Martínez-González, Jorge Andrés Muñoz-Robles, Yolanda Riesgo, Beatriz Perez, Carlos Hagen, Pablo Viguera
Survey on the Situation of Medical Departments in the Pharmaceutical Industry in Spain. Pharmaceutical medicine 38 (3) (2024)
Feng Sun, Alexander Bedenkov, Bi-Cheng Liu, Jiefu Yang, Jin-Fu Xu, Linong Ji, Min Zhou, Shaosen Zhang, Xinli Li, Yuanlin Song, Pingyan Chen, Carmen Moreno
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings. Pharmaceutical medicine 38 (3) (2024)
Ryosuke Kuribayashi, Aya Hariu, Ayuki Nakano, Yasuhiro Kishioka
Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments. Pharmaceutical medicine 38 (3) (2024)
Uchenna Geraldine Elemuwa, Fraden Bitrus, Ibrahim Adekunle Oreagba, Adeline Ijeoma Osakwe, Abiola Sadikat Abiodun, Kenneth Onu, Asmau Abubakar, Angela E Faniyi, Victoria Etuk, Daniel Yuah, Rametu Momodu, Christiana Mojisola Adeyeye
Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria. Pharmaceutical medicine 38 (3) (2024)
Isabel Sanchez-Magro, Susana Gomez-Lus, Javier Martínez-González, Jorge Andrés Muñoz-Robles, Yolanda Riesgo, Beatriz Perez, Carlos Hagen, Pablo Viguera
Survey on the Situation of Medical Departments in the Pharmaceutical Industry in Spain. Pharmaceutical medicine 38 (3) (2024)
Markus Herzig, Simone Eisenhofer, Meike Ruschkowski, Antje Neubert, Astrid Bertsche, Thilo Bertsche, Martina Patrizia Neininger
Authorized or Off-Label Use? A Structured Analysis of Summaries of Product Characteristics with Regard to Authorization in Pediatrics. Pharmaceutical medicine 38 (3) (2024)
Markus Herzig, Simone Eisenhofer, Meike Ruschkowski, Antje Neubert, Astrid Bertsche, Thilo Bertsche, Martina Patrizia Neininger
Authorized or Off-Label Use? A Structured Analysis of Summaries of Product Characteristics with Regard to Authorization in Pediatrics. Pharmaceutical medicine 38 (3) (2024)
Feng Sun, Alexander Bedenkov, Bi-Cheng Liu, Jiefu Yang, Jin-Fu Xu, Linong Ji, Min Zhou, Shaosen Zhang, Xinli Li, Yuanlin Song, Pingyan Chen, Carmen Moreno
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings. Pharmaceutical medicine 38 (3) (2024)
Kevin D Wolter, Asayuki Kamatani, Yumiko Suzuki, Takayuki Imaeda, Ramzi Dagher, Allan Safferman, Rod Junor
A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan. Pharmaceutical medicine 38 (3) (2024)
Kevin D Wolter, Asayuki Kamatani, Yumiko Suzuki, Takayuki Imaeda, Ramzi Dagher, Allan Safferman, Rod Junor
A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan. Pharmaceutical medicine 38 (3) (2024)
Kevin D Wolter, Asayuki Kamatani, Yumiko Suzuki, Takayuki Imaeda, Ramzi Dagher, Allan Safferman, Rod Junor
A Sponsor's Perspective on the Contribution of Regulatory-Required Observational Post-Marketing Studies to Understanding Human Drug Product Benefit/Risk in Japan. Pharmaceutical medicine 38 (3) (2024)
Markus Herzig, Simone Eisenhofer, Meike Ruschkowski, Antje Neubert, Astrid Bertsche, Thilo Bertsche, Martina Patrizia Neininger
Authorized or Off-Label Use? A Structured Analysis of Summaries of Product Characteristics with Regard to Authorization in Pediatrics. Pharmaceutical medicine 38 (3) (2024)
Isabel Sanchez-Magro, Susana Gomez-Lus, Javier Martínez-González, Jorge Andrés Muñoz-Robles, Yolanda Riesgo, Beatriz Perez, Carlos Hagen, Pablo Viguera
Survey on the Situation of Medical Departments in the Pharmaceutical Industry in Spain. Pharmaceutical medicine 38 (3) (2024)
Damir Erceg, Marina Jakirović, Luka Prgomet, Marina Madunić, Mirjana Turkalji
Conducting Drug Treatment Trials in Children: Opportunities and Challenges. Pharmaceutical medicine 38 (3) (2024)
Feng Sun, Alexander Bedenkov, Bi-Cheng Liu, Jiefu Yang, Jin-Fu Xu, Linong Ji, Min Zhou, Shaosen Zhang, Xinli Li, Yuanlin Song, Pingyan Chen, Carmen Moreno
Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings. Pharmaceutical medicine 38 (3) (2024)
Sajita Setia, Elliot Loo, Salil Prakash Shinde, Manmohan Singh, Chew Hooi Wong, Karan Thakkar
Redefining the Role of Medical Affairs Professionals as Innovators and Leaders in Industry-Led Medical Education. Pharmaceutical medicine 38 (3) (2024)
Ryosuke Kuribayashi, Aya Hariu, Ayuki Nakano, Yasuhiro Kishioka
Survey of Data Package and Sample Size of Comparative Clinical Studies for Biosimilar Developments from PMDA Assessments. Pharmaceutical medicine 38 (3) (2024)
Uchenna Geraldine Elemuwa, Fraden Bitrus, Ibrahim Adekunle Oreagba, Adeline Ijeoma Osakwe, Abiola Sadikat Abiodun, Kenneth Onu, Asmau Abubakar, Angela E Faniyi, Victoria Etuk, Daniel Yuah, Rametu Momodu, Christiana Mojisola Adeyeye
Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria. Pharmaceutical medicine 38 (3) (2024)
Uchenna Geraldine Elemuwa, Fraden Bitrus, Ibrahim Adekunle Oreagba, Adeline Ijeoma Osakwe, Abiola Sadikat Abiodun, Kenneth Onu, Asmau Abubakar, Angela E Faniyi, Victoria Etuk, Daniel Yuah, Rametu Momodu, Christiana Mojisola Adeyeye
Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria. Pharmaceutical medicine 38 (3) (2024)

volume 38, number 4, 2024

Cecilia Petrus, Holly Lam
Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences. Pharmaceutical medicine 38 (4) (2024)
Cecilia Petrus, Holly Lam
Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences. Pharmaceutical medicine 38 (4) (2024)
Malia A Belnap, Kaitlin R McManus, Erica N Grodin, Lara A Ray
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder. Pharmaceutical medicine 38 (4) (2024)
Malia A Belnap, Kaitlin R McManus, Erica N Grodin, Lara A Ray
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder. Pharmaceutical medicine 38 (4) (2024)
Eugenia Bastos, Jeff K Allen, Jeff Philip
Statistical Signal Detection Algorithm in Safety Data: A Proprietary Method Compared to Industry Standard Methods. Pharmaceutical medicine 38 (4) (2024)
Gareth Baynam, Simeón Baker, Charles Steward, Marshall Summar, Meghan Halley, Anne R Pariser
Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials. Pharmaceutical medicine 38 (4) (2024)
Malia A Belnap, Kaitlin R McManus, Erica N Grodin, Lara A Ray
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder. Pharmaceutical medicine 38 (4) (2024)
Malia A Belnap, Kaitlin R McManus, Erica N Grodin, Lara A Ray
Endpoints for Pharmacotherapy Trials for Alcohol Use Disorder. Pharmaceutical medicine 38 (4) (2024)
Victor L Van de Wiele, Aaron S Kesselheim, Deborah Gleeson, Zhigang Lu, Sean S Tu, Benjamin N Rome
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA. Pharmaceutical medicine 38 (4) (2024)
Victor L Van de Wiele, Aaron S Kesselheim, Deborah Gleeson, Zhigang Lu, Sean S Tu, Benjamin N Rome
Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA. Pharmaceutical medicine 38 (4) (2024)
Cecilia Petrus, Holly Lam
Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences. Pharmaceutical medicine 38 (4) (2024)
Gareth Baynam, Simeón Baker, Charles Steward, Marshall Summar, Meghan Halley, Anne R Pariser
Increasing Diversity, Equity, Inclusion, and Accessibility in Rare Disease Clinical Trials. Pharmaceutical medicine 38 (4) (2024)
Jon Zdon, Greta-James Chatgilaou, David Henderson, Matthew Britland, Sarah Tregenza, Nathalie McNeil, Dirk Otto, Josie Downey
How Can General Managers Best Leverage Medical Affairs Now and in the Future? Pharmaceutical medicine 38 (4) (2024)
Jon Zdon, Greta-James Chatgilaou, David Henderson, Matthew Britland, Sarah Tregenza, Nathalie McNeil, Dirk Otto, Josie Downey
How Can General Managers Best Leverage Medical Affairs Now and in the Future? Pharmaceutical medicine 38 (4) (2024)
Eugenia Bastos, Jeff K Allen, Jeff Philip
Statistical Signal Detection Algorithm in Safety Data: A Proprietary Method Compared to Industry Standard Methods. Pharmaceutical medicine 38 (4) (2024)
Jon Zdon, Greta-James Chatgilaou, David Henderson, Matthew Britland, Sarah Tregenza, Nathalie McNeil, Dirk Otto, Josie Downey
How Can General Managers Best Leverage Medical Affairs Now and in the Future? Pharmaceutical medicine 38 (4) (2024)
Cecilia Petrus, Holly Lam
Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences. Pharmaceutical medicine 38 (4) (2024)
Jon Zdon, Greta-James Chatgilaou, David Henderson, Matthew Britland, Sarah Tregenza, Nathalie McNeil, Dirk Otto, Josie Downey
How Can General Managers Best Leverage Medical Affairs Now and in the Future? Pharmaceutical medicine 38 (4) (2024)